21/02/2018
Joana Mota-Portugal
Joana Portugal Mota is graduated in Pharmacy (University of Coimbra, Portugal) and PhD in Pharmaceutical Technology (Free University of Berlin, Germany). She is currently Product Development Manager - R&D Department at Lecifarma (Loures, Portugal), Assistant Professor at the School of Sciences and Health Technologies of Lusófona University (Lisbon, Portugal) and Researcher at CBIOS-Research Center for Biosciences and Health Technologies (Lisbon, Portugal).
Fábio Fiúzia Rosa
Fábio Fiúza Rosa is currently a PhD student at Lund University and Coimbra University (Center for Neurosciences and Cell Biology). In 2015, Fabio joined Filipe Pereira’s group
as a master student where he developed a strong interest in deciphering how direct cell
reprogramming can be used to manipulate immune responses. In the past 2 years Fábio
has been developing a technology to generate patient-specific antigen presenting cells,
namely Dendritic Cells, with potential clinical application for cancer treatment. During this period, he has received five awards and submitted a provisional patent application.
Moreover, Fabio is passionate about entrepreneurship, being a co-founder of BRT Blood
Reprogramming Technologies and having participated in several business competitions
to help BRT in the process of technology commercialization.
Cláudia Silva
Cláudia Silva has a Degree in Pharmaceutical Sciences (2003) and a PhD in Pharmacy (Pharmaceutical Technology) by the Faculty of Pharmacy, University of Coimbra since 2008.
In 2008, she joined the R&D group at Bluepharma, Indústria Farmacêutica, SA and since 2009 she worked as the Head of the Research Department. In this 9 years of work in the pharmaceutical industry she gained experience in the areas of pharmaceutical technology, drug delivery, project planning, project management of collaborative R&D projects, knowledge management and RDI management. She also participated in the preparation and planning of 10 QREN project proposals, 6 FP7 project proposals, 10 Horizon 2020 project proposals and 3 Portugal 2020 project proposals. She is co-author of 16 peer-reviewed papers in international journals and co-inventor of a patent.
Currently she is the Head of Research and Innovation of Bluepharma and the COO/deputy CEO of Luzitin.
She complemented her educational and professional training with nationally or internationally certified courses in the areas of Quality Assurance and Management, such as: Executive Training Programme in General Management (Porto Business School), Audit Training (ISO 9001, NP 4457, ISO 14001, OSHAS 18001), Innovation Management Executive Training (COTEC) and Technology Based Entrepreneurship Training (University of Coimbra).
She is also an independent expert for the evaluation of Horizon 2020 project proposals
in the area of Innovation management.
Sofia Corte-Real
Sofia Corte-real developed her professional career in the area of Health Sciences performing different functions, from conducting scientific research and doing a PhD in the area of antibodies and virology, to functions related with the preclinical development of drugs, as well as support to technology and strategy development to facilitate biomedical research, emerging technologies and biotechnology-derived product development.
Her main know-how and interest has been in science-based regulatory strategy, devising and implementing all non-clinical studies, manufacturing and process development studies, interacting with regulatory bodies such as FDA, EMA and Infarmed on a regular basis.
Over the years she has gained an interest in intellectual property (IP), having drafted diverse patents, analyzing FTO as well as revising all IP strategy in various therapeutic areas and with different classes of molecules (bacteriophages, antibodies, small molecules).
Her biggest professional challenge is to direct the R&D Department of a Biopharmaceutical company which includes scientific support of three different technology platforms as well as development of the products in pipeline, in collaboration with China, US and Europe. This has given her competencies in developing full-scale project plans and communicating project expectations to team members and Board stakeholders in a timely and clear fashion.
